U.S. Food and Drug Administration approval of Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have tried at least one other anti-cancer therapy.

CLL progresses slowly, gradually leading to an increase in white blood cells called B lymphocytes. Last year, some 15,680 Americans were diagnosed with CLL and 4,580 died from it, the agency said Wednesday in a news release, citing the National Cancer Institute.

Imbruvica was approved last November to treat people with mantle cell lymphoma.

Approval for CLL was based on clinical studies involving 48 people, the FDA said. Some 58 percent of participants had their cancer shrink after treatment.

Among the most common side effects of the drug were: low blood platelets, diarrhea, bruising, upper respiratory tract infection, fatigue and muscle pain.

Imbruvica is manufactured by Pharmacyclics, based in Sunnyvale, Calif.

More information

The FDA has more about this approval.

Loading video…

PLUS: Working Moms: Making friends and Out East: Bedell Cellars Credit: Newsday

Updated now 2026 Holiday gift guide, Working Moms: Making friends and Out East: Bedell Cellars. Here's a look at some of the exclusive stories you may have missed this week on NewsdayTV.

Loading video…

PLUS: Working Moms: Making friends and Out East: Bedell Cellars Credit: Newsday

Updated now 2026 Holiday gift guide, Working Moms: Making friends and Out East: Bedell Cellars. Here's a look at some of the exclusive stories you may have missed this week on NewsdayTV.

Subscribe

Unlimited Digital AccessOnly 25¢for 6 months

SUBSCRIBESALE ENDS SOON | CANCEL ANYTIME